ClinicalTrials.gg
CompletedNCT06769477Updated Nov 18, 2026

The Effect of Education Given to Type 2 Diabetics on Diabetes Self-management, Health Fatalism and Metabolic Parameters

An interventional study of Experimental Group in Type 2 Diabetes and Type 2 Diabetes Patients, sponsored by Ataturk University. Completed at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ataturk University · Not applicable, Interventional, and Other

How we know

Updated Nov 18, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.

Enrollment
197th of 266
62 · median 100
Started
2025
with 25 others
No phase
150 of 342
33 open now
Registered
241st of 342
by date
Lead sponsor
6 of 342
Ataturk University

Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 197th largest by enrollment of the 266 interventional ones that give a count, is one of 26 that started in 2025, is one of 150 with no phase, and was the 241st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to examine the effects on diabetes self-management, health fatalism and metabolic parameters of individuals with type 2 diabetes. The study will be conducted in a health institution between May 2025 and October 2025 and participants will be assigned to experimental and control groups by simple random sampling method. The experimental group will be trained with motivational interviewing techniques based on the health belief model for 8 weeks, followed by sending reminder SMS for 4 weeks. The control group will receive no intervention. The study is expected to improve the self-care behaviors of individuals with diabetes by creating positive effects on diabetes management and health fatalism.

Read the detailed description

Aim: The aim is to examine the effects of combining the Health Belief Model with Motivational Interviewing techniques on self-management behaviors, perceptions of health fatalism, and metabolic parameters in patients with type 2 diabetes.

Material and Method: This randomized controlled trial was conducted between July 2024 and April 2026. The sample consisted of a total of 62 individuals, including 31 experimental subjects and 31 controls. Data were collected using the "Identification Information Form," "Type 2 Diabetes Self-Management Scale", "Health Fatalism Scale" and "Metabolic Control Monitoring Form." In the experimental group, an 8-week training program based on the Health Belief Model and Motivational Interviewing was implemented; during the 4-week period following the training, support was provided via weekly SMS messages. No intervention was made in the control group. After 3 months, the scales were reapplied to both groups. The data were analyzed using SPSS 22, and t-tests, Mann Whitney U, Wilcoxon, and chi-square tests were used.

Conclusion: Motivational interviews based on the Health Belief Model have been found to increase self-management, reduce health fatalism, and improve metabolic parameters in individuals with type 2 diabetes. Accordingly, it is recommended that this approach be integrated into nursing practices in diabetes care, particularly in primary healthcare settings.

Key Words: Health belief model, health fatalism, metabolic parameters, motivational interviewing, nursing, self-management, type 2 diabetes

03

Conditions studied

  • Type 2 Diabetes
  • Type 2 Diabetes Patients

Keywords

  • health belief model
  • motivational interview
  • self-management
  • health fatalism
  • type 2 diabetes
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having type 2 diabetes for at least 6 months
  • Being between 18 and 65 years old
  • Have sufficient communication skills to answer verbal and written questions and fulfill instructions
  • Becoming literate
  • No physical, cognitive or mental impairment in answering the questions
  • Willingness to participate in research.

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • Being hospitalized in inpatient treatment institutions due to DM or DM complications during the research process
  • The emergence of any health problem that prevents the person from continuing the research
  • Do not leave the study voluntarily.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    group receiving diabetes education with motivational interviewing technique

    Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale will be applied to the experimental group before the training. then, diabetes education will be given to the individuals in the experimental group one day a week with the motivational interviewing technique based on the health belief model. 8 weeks of training will be given in total and then 4 weeks of informative reminder sms will be sent about diabetes education. After the training is over, Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale will be applied.

    Other: Experimental Group

  • No intervention
    group with no intervention

    The control group will be administered the Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale at the first encounter. After 3 months, the Patient Introduction Form, Type 2 DM Self-Management Scale (SMS) and Health Fatalism Scale will be applied again. No application will be made to the control group.

Interventions

  • OtherExperimental Group

    individuals will receive diabetes education with motivational interviewing technique based on health belief model

06

What researchers measure

Primary outcomes

  1. Type 2 DM Self-Management Scale (SMS)

    The scale assesses self-management It has 3 sub-dimensions.These dimensions consist of 11 questions consisting of "Healthy Lifestyle Behaviors" dimension, consisting of 4 questions "Health Services Utilization" dimension and "Blood Sugar Management" dimension. Scoring: Always 5, Often 4, Sometimes 3, Rarely 2, Never 1. (-Healthy Lifestyle Subdimension= HLBD-1+ HLBD-2+ HLBD-3+ HLBD-4+ HLBD-5+ HLBD-6+ HLBD-7+ SYBD-8+ SYBD-9+ SYBD-10+ SYBD-11.) (-Blood Glucose Management Subscale= BSM-1+ BSM-2+ BSM-3+ BSM-4) (-Health Services Utilization Subdimension= SHK-1+ SHK-2+ SHK-3+ SHK-4) (-Diabetes Self-Management Scale score=SMDI Subdimension+CSM Subdimension +SCC Subdimension.) There are no reverse items in the scale. High scores indicate good self-management, low scores indicate and poor self-management. The minimum score that can be obtained from the Type 2 self-management scale is 19 and the maximum score is 95.

    Time frame: three months

Secondary outcomes

  1. Health Fatalism Scale

    The scale consists of one sub-dimension and 17 items. The scale is a Likert-type scale answered as ''strongly disagree'', ''disagree'', ''undecided'', ''agree'', ''strongly agree''. The minimum score obtained from the Health Fatalism Scale is 17 and the maximum score is 85. Cronbach α Coefficient of the scale is 0.91.An increase in the score on the scale indicates an increase in fatalism.

    Time frame: three months

07

Study locations

2 sites
  • Manavgat and Aksu Family Health Center
    Antalya, 07000, Turkey (Türkiye)
  • Manavgat and Aksu Family Health Center
    Antalya, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Aug 2025, 3 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 3 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Feb 2025 → May 2025, primary completion May 2025 → Aug 2025 and completion Jun 2025 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 10, 2025
StartActual
May 1, 2025was Feb 2025
Primary completionActual
Aug 20, 2025was May 2025
CompletionActual
Aug 20, 2025was Jun 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Start date
Feb 1, 2025→May 1, 2025
Nov 18, 2026
Primary completion
May 1, 2025→Aug 20, 2025 (actual)
Nov 18, 2026
Study completion
Jun 1, 2025→Aug 20, 2025 (actual)
Nov 18, 2026
Enrollment
66 (estimated)→62 (actual)
Nov 18, 2026
Eligibility
Maximum age none→65 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore To be over 18 years oldNow Being between 18 and 65 years old
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Start date Feb 1, 2025→May 1, 2025
    Primary completion May 1, 2025→Aug 20, 2025 (now actual)
    Study completion Jun 1, 2025→Aug 20, 2025 (now actual)
    Enrollment 66 (estimated)→62 (actual)
    Eligibility Maximum age none→65 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore To be over 18 years oldNow Being between 18 and 65 years old
    + 6 other changes: identifiers, verification date, oversight details, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06769477
Lead sponsor
Ataturk University
Responsible party
Gülşen Altuntas Çalım (health services teacher in the ministry of national education, Ataturk University) — Principal investigator
First posted
Jan 10, 2025
Start date
May 1, 2025
Primary completion
Aug 20, 2025
Completion
Aug 20, 2025
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion